KIT and gastrointestinal stromal tumor: Since then the landscape of advanced KIT- and PDGFRA-mutant GIST management has evolved to include second-, third- and fourth-line TKIs, sunitinib, regorafenib and ripretinib, as well as avapritinib for advanced PDGFRA D842V mutant GIST.